Welcome to our dedicated page for Lineage Cell Therapeutics SEC filings (Ticker: LCTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Lineage Cell Therapeutics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Lineage Cell Therapeutics's regulatory disclosures and financial reporting.
Lineage Cell Therapeutics director and 10% owner Neal C. Bradsher reported a grant of stock options covering 125,000 common shares. The options have an exercise price of $1.30 per share and expire on July 1, 2036. They were granted on July 1, 2026 as director compensation under Lineage’s 2021 Equity Incentive Plan.
According to the filing, these options will vest and become exercisable on the earlier of July 1, 2027 or the company’s next annual shareholder meeting after the grant date, subject to his continuous service. The report also lists several existing option holdings with exercise prices between $0.8263 and $2.86 per share, expiring from 2029 through 2035.
Lineage Cell Therapeutics director Anula Jayasuriya received a stock option grant covering 125,000 common shares. The options have an exercise price of $1.30 per share and expire on July 1, 2036. This is a compensation-related award, not an open-market purchase.
The option will vest and become exercisable on the earlier of July 1, 2027 and the company’s next annual meeting of shareholders, subject to Jayasuriya’s continuous service with the company. Following this grant, the filing shows 125,000 derivative securities held directly.
Lineage Cell Therapeutics director Michael H. Mulroy received a grant of stock options representing 125,000 common shares. The options carry an exercise price of $1.30 per share and expire on July 1, 2036. This is a compensation-related award, not an open-market purchase or sale.
The options will vest and become exercisable on the earlier of July 1, 2027 or the date of the company’s next annual shareholder meeting, subject to his continuous service with the company.
Lineage Cell Therapeutics director Deborah J. Andrews received a grant of stock options covering 125,000 common shares. The options have an exercise price of $1.3000 per share and expire on July 1, 2036. They were awarded as a compensation-related grant rather than an open-market purchase or sale.
According to the terms, the options will vest and become exercisable on the earlier of July 1, 2027 or the date of Lineage Cell Therapeutics' next annual meeting of shareholders, provided Andrews continues to serve the company through that time. Following this grant, she holds stock options for 125,000 shares directly.
Lineage Cell Therapeutics director Russell Angus received a grant of stock options covering 125,000 common shares. The options have an exercise price of $1.30 per share and expire on July 1, 2036.
According to the footnote, the options will vest and become exercisable on the earlier of July 1, 2027 and the date of Lineage Cell Therapeutics’ next annual meeting of shareholders, in each case only if he continues to serve with the company. After this grant, his reported derivative holdings from this award total 125,000 options.
Lineage Cell Therapeutics director Dipti Amin received a stock option grant covering 125,000 common shares. The option has an exercise price of $1.30 per share and expires on July 1, 2036. It will vest and become exercisable on the earlier of July 1, 2027 and the date of the company’s next annual shareholder meeting, subject to Amin’s continuous service. Following this grant, Amin holds options for 125,000 shares directly.
Lineage Cell Therapeutics held its annual shareholder meeting, where investors elected seven directors to serve until the 2027 meeting. Each nominee, including CEO Brian M. Culley and Chair Angus C. Russell, received over 89.9 million votes in favor, with sizable broker non-votes.
Shareholders also ratified Baker Tilly US, LLP as independent auditor for the 2026 fiscal year and approved, on an advisory basis, the compensation program for named executive officers. Separately, Lineage withdrew its application for a CIRM CLIN2 grant for OPC1 but stated that this withdrawal does not affect its current or planned development of OPC1 in the ongoing DOSED spinal cord injury study.
Lineage Cell Therapeutics, Inc. reported Q1 2026 revenue of $1.7M, up from $1.5M a year earlier, driven mainly by collaboration income. Operating expenses rose to $9.3M, leading to a net loss attributable to Lineage of $4.8M, or $(0.02) per basic share.
Cash, cash equivalents and marketable securities totaled $53.4M as of March 31, 2026, and management believes this will fund planned operations for at least twelve months. The company continues to advance its OpRegen collaboration with Roche, OPC1 spinal cord program, and preclinical pipeline, while using an at-the-market facility and prior warrant financings for capital.
Lineage Cell Therapeutics reported first quarter 2026 results showing modest revenue growth alongside higher R&D investment and continued strategic pipeline progress. Total revenue for the quarter ended March 31, 2026 was $1.7 million, up from $1.5 million a year earlier, mainly from a collaboration with William Demant Invest.
Total operating expenses rose to $9.3 million from $8.0 million, driven by increased R&D spending on OPC1, the ReSonance hearing-loss program, and other preclinical work. Net loss attributable to Lineage was $4.8 million, or $0.02 basic and $0.03 diluted per share, compared with a $4.1 million net loss in 2025.
The company ended the quarter with $53.4 million in cash, cash equivalents, and marketable securities, which it expects to fund planned operations into the second quarter of 2028. Operationally, Lineage highlighted positive three-year OpRegen data in geographic atrophy, treatment of a second chronic spinal cord injury patient with OPC1, launch of its COR1 corneal program, progress on its AlloSCOPE 5D/ILT1 manufacturing initiative, and the formation of a new Scientific Advisory Board and senior clinical leadership.